See more : Archimedes Tech SPAC Partners Co. (ATSPT) Income Statement Analysis – Financial Results
Complete financial analysis of SAB Biotherapeutics, Inc. (SABSW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SAB Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Jiangsu Hengli Hydraulic Co.,Ltd (601100.SS) Income Statement Analysis – Financial Results
- V-Guard Industries Limited (VGUARD.BO) Income Statement Analysis – Financial Results
- Jiangsu Rainbow Heavy Industries Co., Ltd. (002483.SZ) Income Statement Analysis – Financial Results
- Polar Capital Technology Trust plc (PCT.L) Income Statement Analysis – Financial Results
- Braskem S.A. (BRKM5.SA) Income Statement Analysis – Financial Results
SAB Biotherapeutics, Inc. (SABSW)
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 2.24M | 23.90M | 60.88M | 55.24M | 3.44M |
Cost of Revenue | 3.75M | 3.29M | 1.65M | 0.00 | 0.00 |
Gross Profit | -1.51M | 20.61M | 59.22M | 55.24M | 3.44M |
Gross Profit Ratio | -67.28% | 86.23% | 97.28% | 100.00% | 100.00% |
Research & Development | 16.52M | 36.44M | 57.18M | 27.91M | 8.02M |
General & Administrative | 23.80M | 16.38M | 17.09M | 6.77M | 4.10M |
Selling & Marketing | -3.75M | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 20.05M | 16.38M | 17.09M | 6.77M | 4.10M |
Other Expenses | 0.00 | -23.90M | -60.88M | 4.00K | 2.59K |
Operating Expenses | 40.31M | 28.92M | 13.39M | 34.68M | 12.12M |
Cost & Expenses | 40.31M | 28.92M | 13.39M | 34.68M | 12.12M |
Interest Income | 584.97K | 71.07K | 23.12K | 26.13K | 113.13K |
Interest Expense | 315.28K | 301.58K | 294.46K | 469.15K | 428.48K |
Depreciation & Amortization | 3.75M | 3.29M | 1.65M | 548.18K | 323.41K |
EBITDA | -38.08M | -15.12M | -15.20M | 21.14M | -8.23M |
EBITDA Ratio | -1,700.56% | -113.62% | -19.24% | 38.26% | -239.25% |
Operating Income | -38.08M | -28.92M | -13.39M | 20.56M | -8.67M |
Operating Income Ratio | -1,700.56% | -120.97% | -22.00% | 37.22% | -252.01% |
Total Other Income/Expenses | -4.12M | 10.20M | -3.75M | -439.02K | -312.75K |
Income Before Tax | -42.19M | -18.72M | -17.14M | 20.12M | -8.99M |
Income Before Tax Ratio | -1,884.50% | -78.29% | -28.16% | 36.42% | -261.09% |
Income Tax Expense | 0.00 | 25.63K | 299.95K | 473.15K | 431.07K |
Net Income | -42.19M | -18.74M | -17.44M | 20.12M | -9.42M |
Net Income Ratio | -1,884.50% | -78.40% | -28.66% | 36.42% | -273.62% |
EPS | -7.64 | -4.31 | -6.38 | 7.92 | -0.22 |
EPS Diluted | -7.64 | -4.31 | -6.38 | 7.45 | -0.22 |
Weighted Avg Shares Out | 5.52M | 4.35M | 2.73M | 2.54M | 43.47M |
Weighted Avg Shares Out (Dil) | 5.52M | 4.35M | 2.73M | 2.70M | 43.47M |
Source: https://incomestatements.info
Category: Stock Reports